A Clinical Study of the Safety and Efficacy of MEBO® Wound Ointment in Subjects With Diabetic Foot Ulcers (Pilot)
Launched by SKINGENIX, INC. · Jun 28, 2010
Trial Information
Current as of May 15, 2025
Completed
Keywords
ClinConnect Summary
This is a phase II, randomized, controlled, two-center pilot study designed to assess the safety and efficacy of MEBO in the treatment of subjects with DFUs. Subjects meeting entry criteria will be randomly assigned in a 1:1 ratio for up to 8 weeks of treatment with either MEBO or SOC.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or female ≥18 years of age
- • Able and willing to provide informed consent
- • Able and willing to comply with protocol visits and procedures
- • Target ulcer duration of ≥4 weeks
- Exclusion Criteria:
- • Ulcer of a non-diabetic pathophysiology
- • Known or suspected allergies to any of the components of MEBO
- • Malignancy on target ulcer foot
- • Non-compliance in the screening or run-in period
About Skingenix, Inc.
Skingenix, Inc. is a pioneering biotechnology company focused on developing innovative therapeutic solutions for skin-related conditions. With a commitment to advancing dermatological care, Skingenix harnesses cutting-edge research and technology to create novel treatments aimed at improving patient outcomes. The company collaborates with leading experts in the field and engages in rigorous clinical trials to ensure the safety and efficacy of its products. Through its dedication to scientific excellence and patient-centered approaches, Skingenix is poised to make significant contributions to the dermatology landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
New Haven, Connecticut, United States
Patients applied
Trial Officials
Robert S Kirsner, MD, PhD
Study Chair
University of Miami
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials